BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 25226613)

  • 1. A novel action mechanism for MPT0G013, a derivative of arylsulfonamide, inhibits tumor angiogenesis through up-regulation of TIMP3 expression.
    Wang CY; Liou JP; Tsai AC; Lai MJ; Liu YM; Lee HY; Wang JC; Pan SL; Teng CM
    Oncotarget; 2014 Oct; 5(20):9838-50. PubMed ID: 25226613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TIMP3 expression associates with prognosis in colorectal cancer and its novel arylsulfonamide inducer, MPT0B390, inhibits tumor growth, metastasis and angiogenesis.
    Huang HL; Liu YM; Sung TY; Huang TC; Cheng YW; Liou JP; Pan SL
    Theranostics; 2019; 9(22):6676-6689. PubMed ID: 31588243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Robustaflavone induces G0/G1 cell cycle arrest and apoptosis in human umbilical vein endothelial cells and exhibits anti-angiogenic effects in vivo.
    Sim WK; Park JH; Kim KY; Chung IS
    Sci Rep; 2020 Jul; 10(1):11070. PubMed ID: 32632123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589.
    Qian DZ; Kato Y; Shabbeer S; Wei Y; Verheul HM; Salumbides B; Sanni T; Atadja P; Pili R
    Clin Cancer Res; 2006 Jan; 12(2):634-42. PubMed ID: 16428510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anticancer activity of MPT0G157, a derivative of indolylbenzenesulfonamide, inhibits tumor growth and angiogenesis.
    Huang YC; Huang FI; Mehndiratta S; Lai SC; Liou JP; Yang CR
    Oncotarget; 2015 Jul; 6(21):18590-601. PubMed ID: 26087180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rhizoma Paridis ethanol extract selectively inhibits the proliferation of HUVECs comparing to Lovo cells and shows anti-angiogenesis effects in a mouse model.
    Qian X; Zhu L; Hu J; Li M; Xie L; Wang L; Yu L; Liu B
    J Ethnopharmacol; 2012 Aug; 143(1):256-61. PubMed ID: 22750432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
    Huang SW; Lien JC; Kuo SC; Huang TF
    Carcinogenesis; 2012 May; 33(5):1022-30. PubMed ID: 22436611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Carnosine exerts antitumor activity against bladder cancers in vitro and in vivo via suppression of angiogenesis.
    Hwang B; Shin SS; Song JH; Choi YH; Kim WJ; Moon SK
    J Nutr Biochem; 2019 Dec; 74():108230. PubMed ID: 31683101
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Norcantharidin: a potential antiangiogenic agent for gallbladder cancers in vitro and in vivo.
    Zhang JT; Fan YZ; Chen CQ; Zhao ZM; Sun W
    Int J Oncol; 2012 May; 40(5):1501-14. PubMed ID: 22200632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo monitoring of the anti-angiogenic therapeutic effect of the pan-deacetylase inhibitor panobinostat by small animal PET in a mouse model of gastrointestinal cancers.
    Maschauer S; Gahr S; Gandesiri M; Tripal P; Schneider-Stock R; Kuwert T; Ocker M; Prante O
    Nucl Med Biol; 2016 Jan; 43(1):27-34. PubMed ID: 26702784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SKLB-M8 induces apoptosis through the AKT/mTOR signaling pathway in melanoma models and inhibits angiogenesis with decrease of ERK1/2 phosphorylation.
    Wang J; Yang Z; Wen J; Ma F; Wang F; Yu K; Tang M; Wu W; Dong Y; Cheng X; Nie C; Chen L
    J Pharmacol Sci; 2014; 126(3):198-207. PubMed ID: 25341684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eriocalyxin B, a natural diterpenoid, inhibited VEGF-induced angiogenesis and diminished angiogenesis-dependent breast tumor growth by suppressing VEGFR-2 signaling.
    Zhou X; Yue GG; Liu M; Zuo Z; Lee JK; Li M; Tsui SK; Fung KP; Sun H; Pu J; Lau CB
    Oncotarget; 2016 Dec; 7(50):82820-82835. PubMed ID: 27756875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DCT015, a new sorafenib derivate, inhibits tumor growth and angiogenesis in gastric cancer models.
    Wang W; Wang H; Ni Y; Yao Z; Ye L; Tian J
    Tumour Biol; 2016 Jul; 37(7):9221-32. PubMed ID: 26768619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of lysine acetyltransferases impairs tumor angiogenesis acting on both endothelial and tumor cells.
    Di Martile M; Gabellini C; Desideri M; Matraxia M; Farini V; Valentini E; Carradori S; Ercolani C; Buglioni S; Secci D; Andreazzoli M; Del Bufalo D; Trisciuoglio D
    J Exp Clin Cancer Res; 2020 Jun; 39(1):103. PubMed ID: 32498717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. KRC-408, a novel c-Met inhibitor, suppresses cell proliferation and angiogenesis of gastric cancer.
    Hong SW; Jung KH; Park BH; Zheng HM; Lee HS; Choi MJ; Yun JI; Kang NS; Lee J; Hong SS
    Cancer Lett; 2013 May; 332(1):74-82. PubMed ID: 23348694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SKLB610: a novel potential inhibitor of vascular endothelial growth factor receptor tyrosine kinases inhibits angiogenesis and tumor growth in vivo.
    Cao ZX; Zheng RL; Lin HJ; Luo SD; Zhou Y; Xu YZ; Zeng XX; Wang Z; Zhou LN; Mao YQ; Yang L; Wei YQ; Yu LT; Yang SY; Zhao YL
    Cell Physiol Biochem; 2011; 27(5):565-74. PubMed ID: 21691074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phosphodiesterase inhibitor, pentoxifylline enhances anticancer activity of histone deacetylase inhibitor, MS-275 in human breast cancer in vitro and in vivo.
    Nidhyanandan S; Boreddy TS; Chandrasekhar KB; Reddy ND; Kulkarni NM; Narayanan S
    Eur J Pharmacol; 2015 Oct; 764():508-519. PubMed ID: 26209365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anticancer effects of KI-10F: a novel compound affecting apoptosis, angiogenesis and cell growth in colon cancer.
    Hong SW; Jung KH; Choi MJ; Kim DY; Lee HS; Zheng HM; Li GY; El-Deeb IM; Park BS; Lee SH; Hong SS
    Int J Oncol; 2012 Nov; 41(5):1715-22. PubMed ID: 22941304
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fisetin inhibits various attributes of angiogenesis in vitro and in vivo--implications for angioprevention.
    Bhat TA; Nambiar D; Pal A; Agarwal R; Singh RP
    Carcinogenesis; 2012 Feb; 33(2):385-93. PubMed ID: 22139440
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Formononetin, a novel FGFR2 inhibitor, potently inhibits angiogenesis and tumor growth in preclinical models.
    Wu XY; Xu H; Wu ZF; Chen C; Liu JY; Wu GN; Yao XQ; Liu FK; Li G; Shen L
    Oncotarget; 2015 Dec; 6(42):44563-78. PubMed ID: 26575424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.